Frequently Asked Questions about Helminthic Therapy

DESCRIPTION / INFORMATION

 

Helminthic therapy is the deliberate introduction of selected parasitic worms, or particular developmental stages of those worms, in an attempt to alter the immune system and treat inflammatory, allergic, or autoimmune disease.

The idea developed from observations that immune-mediated diseases such as allergies, inflammatory bowel disease, and some autoimmune disorders are more common in highly industrialized populations where exposure to many parasites and microorganisms has greatly declined. Helminths have evolved sophisticated ways of modifying their hosts’ immune responses so that they can survive for months or years without being eliminated. Researchers have therefore asked whether some of those immunoregulatory effects might be therapeutically useful.

The hypothesis is biologically interesting, and controlled human trials have demonstrated that selected helminths can alter immune responses. However, evidence that deliberate helminth infection produces meaningful clinical benefit has been inconsistent. Several larger randomized trials have failed to confirm promising results from earlier small studies. No helminthic therapy is currently FDA-approved for treating inflammatory, allergic, autoimmune, or neurologic disease in the United States.

These 20 questions explain the organisms used in helminthic therapy, how they affect the immune system, what clinical studies have found, what risks and regulatory issues remain, and why researchers are increasingly interested in helminth-derived molecules as possible alternatives to administering living parasites.

At a Glance: Organisms Used or Proposed for Helminthic Therapy

Organism	Therapeutic stage	Natural host / relationship to humans	Persistence in humans	Research status
Trichuris suis  (pig whipworm)	Embryonated ova (TSO) swallowed orally	Pig is the normal host; humans are an abnormal host	Usually relatively short-lived in humans	Studied in randomized trials of Crohn’s disease, ulcerative colitis, allergic disease, and other conditions
Necator americanus  (human hookworm)	Infective third-stage larvae applied to skin	Humans are a natural host	Adults may persist for years	Studied experimentally in asthma, celiac disease, multiple sclerosis, and other conditions
Hymenolepis diminuta (rat tapeworm)	Cysticercoid larval stage swallowed orally	Rodents are usual definitive hosts; humans can become infected accidentally	Often limited, but human infection can occur	Used mainly in self-treatment communities; far less controlled clinical evidence
Trichuris trichiura (human whipworm)	Embryonated eggs	Humans are the natural host	Can establish persistent infection	Reported in self-treatment but is a recognized human pathogen and has not been a major organism in modern therapeutic trials

These organisms are not biologically interchangeable. They differ in where they live, how long they survive, how they are transmitted, what immune responses they produce, and what risks they pose.

QUESTIONS

1. What is helminthic therapy?

Helminthic therapy is the deliberate exposure of a person to a selected helminth (or developmental stage of a helminth) with the goal of changing immune activity in a way that might reduce inflammatory, allergic, or autoimmune disease.

Helminths are multicellular parasitic worms. They include nematodes, or roundworms; cestodes, or tapeworms; and trematodes, or flukes.

Therapeutic research has focused mainly on organisms thought to have a relatively manageable life cycle or safety profile, particularly Trichuris suis ova and Necator americanus larvae.

The goal is not simply to produce a parasitic infection. Researchers try to create a controlled exposure capable of producing immunologic effects while limiting the harm that naturally acquired helminth infections can cause.

That balance is difficult, because the same ability that makes a helminth potentially useful (its ability to manipulate the human immune system) is part of what enables the parasite to survive in its host.

2. Which organisms have been used in helminthic therapy?

The two organisms with the greatest history of controlled human research are Trichuris suis and Necator americanus.

Trichuris suis ova (TSO)

T. suis is the pig whipworm. Embryonated eggs are swallowed. Because humans are not its normal host, most larvae do not develop into long-lived mature worms in people. This was one reason TSO became attractive for early clinical trials. Repeated doses were therefore generally required in research protocols.

Necator americanus

N. americanus is a human hookworm. Infective larvae penetrate the skin, migrate through the bloodstream and lungs, are swallowed, and mature into adults in the small intestine. Because humans are its natural host, infection can persist for years.

Hymenolepis diminuta cysticercoids (HDC)

The rat tapeworm has also been used by some people who self-treat inflammatory disorders. The cysticercoid stage is ingested. Controlled clinical evidence is much more limited than for TSO or hookworm, and H. diminuta remains a zoonotic parasite capable of establishing human infection.

Trichuris trichiura

The human whipworm has occasionally been used in self-treatment. Unlike T. suis, however, humans are its natural host, and infection can become chronic and pathogenic. It should therefore not be treated simply as another equivalent “therapeutic worm.”

3. How might helminths change the immune system?

Helminths have evolved multiple methods of preventing the host immune system from eliminating them.

They can alter:

• regulatory T-cell activity;
• T-helper-cell responses;
• macrophage behavior;
• dendritic-cell function;
• antibody production;
• inflammatory cytokines;
• intestinal barrier responses;
• tissue repair; and
• interactions between the immune system and gut microbiome.

Older explanations often described helminth therapy mainly as shifting immunity from a Th1 response toward a Th2 response. That is now recognized as too simple.

Helminths release many proteins, glycans, lipids, small molecules, and extracellular vesicles that interact with both innate and adaptive immunity. Some promote regulatory responses such as IL-10 production and regulatory T-cell activity, while others modify inflammation through different pathways.

The important point is that helminths do not simply “turn the immune system down.” They reshape immune regulation in complex, species-specific ways.

4. What diseases have been studied with helminthic therapy?

Human studies have investigated helminth therapy for conditions including:

• Crohn’s disease;
• ulcerative colitis;
• celiac disease;
• multiple sclerosis;
• asthma;
• allergic rhinitis; and
• other inflammatory or allergic disorders.

Self-treatment communities have reported use for many additional conditions, including eczema, food intolerance, arthritis, autism-associated symptoms, migraine, and psychiatric disorders.

Those reports should not be confused with clinical evidence.

A treatment being tried by patients (or even appearing biologically plausible) does not establish that it is effective.

Controlled studies have produced mixed results, and several of the diseases initially considered especially promising have not shown clear benefit in larger trials.

5. Is helminthic therapy safe?

“Safe” depends heavily on which helminth, what dose, which patient, and how long the infection persists.

Several controlled trials of low-dose TSO or N. americanus have reported acceptable short-term tolerability. For example, a randomized Crohn’s disease trial using up to 7,500 T. suis ova every two weeks found no serious treatment-related safety signal, even though the therapy did not show clinical efficacy.

Similarly, experimental low-dose hookworm studies have generally been reasonably well tolerated, although skin reactions, gastrointestinal symptoms, eosinophilia, and other effects occur.

But this does not mean that helminths are harmless.

Natural helminth infections can cause substantial disease. Hookworms feed on blood and can contribute to iron-deficiency anemia at sufficient burden. Whipworms can cause intestinal inflammation, diarrhea, blood loss, and other complications. Individual susceptibility also varies.

Clinical-trial safety data from carefully selected adults receiving controlled doses should therefore not automatically be applied to unsupervised self-treatment, different species, children, pregnancy, or medically vulnerable patients.

6. What are the main risks and side effects?

Risks depend strongly on the organism.

With Necator americanus, possible effects include:

• itching and rash where larvae enter the skin;
• temporary respiratory symptoms during larval migration;
• abdominal discomfort;
• nausea or diarrhea;
• eosinophilia;
• iron loss; and
• anemia if worm burden becomes excessive.

In a randomized MS trial, application-site skin discomfort was much more common in hookworm recipients than placebo recipients.

With T. suis ova, gastrointestinal symptoms may occur, although controlled trials have generally found the organism reasonably well tolerated over the periods studied.

With H. diminuta, human infection is usually uncommon but is a recognized zoonosis. Gastrointestinal symptoms can occur, and established infections may require antiparasitic treatment.

Other concerns include:

• unintended excessive colonization;
• altered responses to infection or vaccination;
• interactions with immune-modifying drugs;
• contamination of inadequately manufactured biological material;
• infection with an organism other than the one advertised;
• pregnancy-related uncertainty;
• effects in immunocompromised people; and
• delayed diagnosis when disease symptoms are attributed incorrectly to the therapy.

The idea of a universally “safe therapeutic helminth” is therefore misleading.

7. Is helminthic therapy FDA-approved or legally available in the United States?

No helminthic organism is currently FDA-approved as a treatment for inflammatory, autoimmune, allergic, or neurologic disease.

FDA considers therapeutic helminths intended to prevent, treat, or cure disease to be biological products.

FDA Import Alert 57-21 specifically lists:

• hookworm;
• Necator americanus;
• Trichuris trichiura;
• Trichuris suis ova;
• Hymenolepis diminuta;
• and their therapeutic eggs or larvae.

The alert states that imported products intended for human therapeutic use may be detained unless covered by an effective Investigational New Drug application or an applicable biologics license. FDA also cites concerns about manufacturing controls, adventitious infectious agents, contaminants, and allergens.

Therefore, the common statement that helminths can simply be imported for “personal use” because they are not ordinary medicines is inaccurate.

Within formal research, therapeutic helminths may be studied under appropriate investigational regulatory oversight.

8. How is helminthic therapy administered?

Administration depends entirely on the species and life-cycle stage.

Necator americanus

In experimental trials, infective third-stage larvae have been placed on the skin under a dressing. The larvae penetrate the skin and eventually mature into adult hookworms in the small intestine.

Trichuris suis ova

Embryonated eggs are swallowed in a liquid preparation.

Research protocols have varied considerably. Trials have used doses from hundreds to several thousand ova, sometimes repeated every two weeks.

Hymenolepis diminuta

The cysticercoid stage has been swallowed in self-treatment practice and experimental descriptions. Controlled therapeutic trials are much more limited.

There is no universally accepted clinical dosing protocol for helminthic therapy.

Dosing schedules found on commercial or self-treatment websites should not be presented as established medical regimens.

9. How quickly does helminthic therapy work, and how long do the organisms survive?

There is no evidence-based answer that applies to all therapeutic helminths.

The draft’s estimate that benefits generally appear after 3-9 months reflects mainly self-treatment experience rather than a validated clinical rule.

Different organisms behave very differently.

T. suis generally persists only temporarily in humans, which is why clinical trials often administered repeated ova.

N. americanus can establish a chronic human infection lasting years.

H. diminuta often does not persist indefinitely in humans, although established human infections do occur.

More importantly, organism survival is not the same thing as therapeutic benefit. An immune response can occur without clinical improvement, and persistent infection does not prove continued effectiveness.

10. Where do therapeutic helminths come from, and how are they manufactured?

In clinical research, the organism should be produced under carefully controlled conditions that address:

• species identity;
• developmental stage;
• dose;
• microbial contamination;
• purity;
• storage;
• viability; and
• batch consistency.

Outside formal research, commercial suppliers have offered organisms directly to consumers. Such suppliers should not be assumed to operate under the manufacturing, quality-control, inspection, and adverse-event-reporting systems required of licensed pharmaceutical or biological-product manufacturers.

FDA’s import alert specifically states that the agency may lack information about manufacturing controls, release testing, adventitious agents, and contaminants in imported therapeutic helminth products.

For a living therapeutic organism, quality control is part of safety.

Knowing the correct species is not enough; one must also know what else may be present in the preparation.

11. Can therapeutic helminths multiply inside the body or spread to another person?

The answer depends on the organism.

Adult N. americanus worms do not multiply directly inside one host. They mate and produce eggs, which leave the body in feces. The eggs must develop in appropriate environmental conditions before becoming infectious larvae. Therefore, ordinary direct person-to-person transmission does not occur.

T. suis likewise has an environmental stage. Eggs passed in feces must mature outside the body before becoming infectious. Humans are not its normal host, and mature persistent infections are uncommon.

H. diminuta requires an arthropod intermediate host, such as a grain beetle, before the cysticercoid stage becomes infective to a mammalian host. Direct person-to-person transmission therefore is not expected.

T. trichiura is different because humans are its natural host, although its eggs also require development in the environment before becoming infectious.

Thus, “they don’t multiply inside you” is partly correct but oversimplified. Therapeutic helminths have different life cycles, and some can establish persistent adult infections and produce eggs.

12. What does the scientific evidence show about effectiveness?

The evidence is much less convincing than early enthusiasm suggested.

Ulcerative colitis

A small 2005 randomized trial of T. suis ova in 54 patients found greater clinical improvement with TSO than placebo, although remission rates were not significantly different.

That result stimulated substantial interest.

However, a much larger 2024 randomized, double-blind, placebo-controlled trial involving 119 patients with moderate ulcerative colitis found that 24 weeks of TSO was not superior to placebo for clinical remission, clinical response, steroid-free remission, or endoscopic remission.

Crohn’s disease

A 2017 randomized trial involving 252 adults found that TSO produced a measurable immunologic response but no clinically meaningful advantage over placebo for remission or response.

Asthma and allergic disease

A randomized trial of experimental hookworm infection in asthma did not demonstrate significant improvement in asthma outcomes.

Reviews of allergic-rhinitis trials likewise have not demonstrated convincing symptomatic benefit.

Celiac disease

Hookworm trials have produced intriguing immunologic and symptom findings, but a larger randomized placebo-controlled study did not show restoration of tolerance to sustained moderate gluten consumption.

Multiple sclerosis

A randomized hookworm trial showed immunologic effects, including increased regulatory T cells, but its primary MRI outcome was not statistically significant.

Overall, helminths clearly can alter human immunity. What remains uncertain is whether those immune changes can be converted into reliable, clinically meaningful treatment benefits.

13. How much does helminthic therapy cost, and is it covered by insurance?

There is no standardized medical price because helminthic therapy is not an FDA-approved routine treatment in the United States.

Commercial self-treatment programs may advertise initial and recurring costs, but those prices reflect private suppliers rather than an established medical reimbursement system.

Health insurance generally should not be assumed to cover organisms purchased for unapproved self-treatment.

Clinical-trial participants may receive study-related treatment under the rules of the individual research protocol.

For an experimental biological therapy, price should not be treated as a measure of quality, safety, or legitimacy.

14. Should a physician supervise helminthic therapy, and can regular medications be continued?

A person considering deliberate helminth infection should discuss it with an appropriately qualified clinician.

That does not mean a physician will prescribe or endorse the treatment. Because therapeutic helminths are not approved routine therapies, many clinicians will reasonably recommend established treatments or clinical-trial participation instead.

Patients should not stop prescribed medications because they begin helminthic therapy.

Interactions between therapeutic helminths and immunosuppressive drugs, biologics, corticosteroids, anticoagulants, or other therapies have not been adequately studied for most situations.

Medical monitoring may also be relevant for:

• blood counts;
• iron status;
• eosinophilia;
• gastrointestinal symptoms;
• worsening of the underlying disease; and
• unexpected infection or inflammatory symptoms.

The safest scientifically informative setting remains a properly designed clinical trial.

15. What should someone expect during the first months, and are “maintenance” or “top-up” doses needed?

There is no validated universal maintenance schedule.

The answer depends on the organism.

T. suis generally does not persist for long periods in humans, so clinical studies often used repeated dosing.

N. americanus can establish a long-lived infection, so frequent re-dosing is biologically unnecessary simply to keep worms present.

H. diminuta behaves differently again.

Commercial descriptions of regular “top-ups” come largely from self-treatment communities rather than evidence-based treatment guidelines.

Symptoms after exposure also differ according to the organism. Hookworm larvae may cause an itchy skin reaction shortly after application, followed by gastrointestinal symptoms as adult infection develops. TSO exposure is primarily gastrointestinal.

A patient should not assume that unpleasant symptoms are evidence that the treatment is “working” or that increasing the number of organisms will improve effectiveness.

16. What is the “hygiene hypothesis” or “old friends hypothesis,” and does it prove that helminth therapy should work?

No.

The original hygiene hypothesis proposed that reduced childhood exposure to infections might contribute to increasing allergic disease in industrialized societies.

The broader old friends hypothesis focuses less on ordinary childhood infections and more on the microorganisms and parasites with which humans co-evolved and that may help shape immune regulation.

Helminths became particularly interesting because chronic infection clearly stimulates regulatory immune mechanisms that help limit inflammation.

However, several steps separate that observation from a treatment recommendation:

Population association → biological mechanism → experimental effect → clinical benefit.

Evidence for the first two does not automatically establish the last.

Modern work also emphasizes that different helminth species affect immunity differently. There is no single generic “worm effect.”

The hypothesis therefore provides a reason to investigate helminths, not proof that deliberate infection is therapeutically beneficial.

17. If problems occur, can therapeutic helminths be removed?

Often, yes, but this should not be interpreted as making deliberate infection risk-free.

Many established human helminths can be treated with anthelmintic drugs, although the appropriate medication depends on the species.

For example, established hookworm infections are ordinarily treated with antiparasitic drugs such as albendazole or mebendazole in conventional clinical practice.

Human H. diminuta infections have been treated successfully with drugs such as praziquantel or niclosamide.

Eradication may be considered when:

• side effects become unacceptable;
• anemia or other complications occur;
• the underlying illness worsens;
• another treatment requires removal of the organism; or
• the patient chooses to discontinue colonization.

But treatment failure, diagnostic uncertainty, or persistent biological effects can occur.

An intentionally established infection should therefore not be approached as though it can always be switched off instantly.

18. How is controlled helminthic therapy different from an ordinary parasitic infection?

The intention is different, but the biology is related.

Researchers attempt to reduce risk by selecting:

• a particular species;
• a known developmental stage;
• a relatively low dose;
• screened study participants;
• defined administration procedures; and
• medical follow-up.

Natural infection is uncontrolled. A person may receive a large or repeated exposure, have nutritional deficiencies or other infections, or develop a high parasite burden.

This distinction is important because helminths remain major causes of disease worldwide. The therapeutic hypothesis does not mean that natural helminth infections are beneficial or that eliminating pathogenic parasitic disease was a mistake.

The scientific question is much narrower:

Can a carefully chosen helminth—or the molecules it produces—provide useful immune regulation at a level where benefits exceed risks?

Controlled research attempts to answer that question without romanticizing parasitic disease.

19. Could helminth-derived molecules provide the benefits without using living worms?

Possibly, and this may ultimately prove more practical than live-organism therapy.

Helminths release many substances that help them regulate the host immune system, including:

• proteins;
• peptides;
• glycoproteins;
• lipids;
• carbohydrates;
• nucleic acids;
• metabolites; and
• extracellular vesicles.

Researchers are attempting to identify which of these molecules produce desirable immunoregulatory effects.

A purified or manufactured molecule could have important advantages over a living parasite:

• standardized dose;
• defined composition;
• easier manufacturing control;
• no persistent infection;
• no egg production or transmission;
• easier pharmacologic testing;
• easier discontinuation; and
• potentially simpler regulatory oversight.

A 2024 review described a growing range of helminth-derived molecules with immunoregulatory potential, while emphasizing that much of this work remains preclinical.

The future of “helminth therapy” may therefore involve learning from helminths without necessarily putting living worms into patients.

20. What are the most important unanswered questions about helminthic therapy?

Several fundamental questions remain.

Which diseases, if any, truly benefit?
Immune modulation does not necessarily translate into clinical improvement.

Which organism is best?
T. suis, N. americanus, H. diminuta, and other helminths have very different biology.

What dose is appropriate?
Too little may have no useful effect; too much may cause disease.

When in the course of disease should treatment occur?
Immune intervention that is ineffective in established disease might theoretically behave differently earlier in life or earlier in disease development.

Which patients are most likely to respond?
Genetics, microbiome composition, prior parasite exposure, disease subtype, diet, and medications may all matter.

Are living organisms necessary?
Helminth-derived proteins, metabolites, or extracellular vesicles may eventually reproduce useful immune effects more safely.

What are the long-term consequences?
Most controlled studies have followed relatively small groups for limited periods.

How should products be manufactured and regulated?
A living organism presents challenges involving identity, purity, contaminants, viability, dose, storage, and batch consistency.

The field therefore remains scientifically valuable even though current clinical evidence does not support routine helminthic therapy.

The most important lesson so far may be that parasites have taught researchers a great deal about immune regulation, even if deliberately infecting patients does not ultimately become the preferred way to use that knowledge.

REFERENCES

Croese, J., Giacomin, P., Navarro, S., et al. (2020). Randomized, placebo-controlled trial of experimental hookworm infection for improving gluten tolerance in celiac disease. Clinical and Translational Gastroenterology, 11.
PubMed record

Evans, H., Mitre, E., & colleagues. (2021). Use of helminth therapy for management of ulcerative colitis and Crohn’s disease: A systematic review.
Free full-text review

Huang, X., Zeng, L.-R., Chen, F.-S., Zhu, J.-P., & Zhu, M.-H. (2018). Trichuris suis ova therapy in inflammatory bowel disease: A meta-analysis.
PubMed record

Prosberg, M. V., Halkjær, S. I., Lo, B., et al. (2024). Probiotic treatment of ulcerative colitis with Trichuris suis ova: A randomized, double-blinded, placebo-controlled clinical trial (the PROCTO trial). Journal of Crohn’s and Colitis, 18(11), 1879-1893. https://doi.org/10.1093/ecco-jcc/jjae095.
PubMed record

Rook, G. A. W. (2023). The old friends hypothesis: Evolution, immunoregulation and essential microbial inputs.
Free full text

Schölmerich, J., Fellermann, K., Seibold, F. W., et al. (2017). A randomized, double-blind, placebo-controlled trial of Trichuris suis ova in active Crohn’s disease. Journal of Crohn’s and Colitis, 11(4), 390-399. https://doi.org/10.1093/ecco-jcc/jjw184.
PubMed record and free full text

Summers, R. W., Elliott, D. E., Urban, J. F., Jr., Thompson, R. A., & Weinstock, J. V. (2005). Trichuris suis therapy for active ulcerative colitis: A randomized controlled trial. Gastroenterology, 128(4), 825-832. https://doi.org/10.1053/j.gastro.2005.01.005.
PubMed record

Szuba, M., Stachera, W., Piwko, A., et al. (2024). Geohelminths: Use in the treatment of selected human diseases. Pathogens, 13(8), 703. https://doi.org/10.3390/pathogens13080703.
PubMed record and free full text

Tanasescu, R., Tench, C. R., Constantinescu, C. S., et al. (2020). Hookworm treatment for relapsing multiple sclerosis: A randomized double-blinded placebo-controlled trial. JAMA Neurology, 77(9), 1089-1098. https://doi.org/10.1001/jamaneurol.2020.1118.
PubMed record and free full text

U.S. Food and Drug Administration. (current). Import Alert 57-21: Detention without physical examination of unapproved products containing helminths intended for therapeutic use.
FDA Import Alert 57-21

Zhang, Y., Shen, C., Zhu, X., Leow, C. Y., Ji, M., & Xu, Z. (2024). Helminth-derived molecules: Pathogenic and pharmacopeial roles. Journal of Biomedical Research, 38(6), 547-568. https://doi.org/10.7555/JBR.38.20240177.
PubMed record
Free full text